Hardman & Co Monthly: July 2024
In 2023, and for the second year running, the Hardman & Co sector index declined, by 3.7%, underperforming both the FTSE 100 and the FTSE All-Share...
193 Views
Hardman & Co Research: ICG Enterprise Trust Plc (ICGT): CM day 2024 - defensive growth value creation
The key messages from ICGT’s June 2024 shareholder seminar were i) ICGT has a focused and differentiated investment strategy with a dedicated...
312 Views
Tissue Regenix Group PLC - Hardman & Co Insight: Survival of the UK life sciences sector
For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This...
106 Views
Hardman & Co Research: Shield Therapeutics (STX): Cash management is key
Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on...
163 Views
ICG Enterprise Trust - FY’24: portfolio companies performing strongly
The key message from ICGT’s FY’24 results (to January) is the continued strength of the operating companies, which keep delivering mid-teen EBITDA...
117 Views